Lupus & antiphospholipid syndrome
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and pneumococcal polysaccharide vaccine (PPSV23) compared with PPSV23 alone in systemic lupus erythematosus
Authors' conclusion
Both vaccination strategies are safe with adequate antibody response.
Study context
- Population
- Adults with SLE (ACR 2019 criteria), inactive disease, stable immunosuppression for 3 months and prednisolone ≤10 mg/day40 enrolled per SLE arm plus 15 healthy adults
- Participants
- 40 / 40 / 15
- Comparison
- Sequential PCV10 followed by PPSV23 vs PPSV23 alone
- Sequentialn = 40
- PPSV23n = 40reference
- Healthy controlsn = 15
- Primary endpoint
- Twofold increase in antibodies in 3/5 serotypes
- Follow-up
- 12-14 weeks
Methodological detailstwo cohorts recruited independently without randomisation, healthy control comparison for PPSV23 response
- Two cohorts recruited independently without randomisation
- Healthy control comparison for PPSV23 response
Primary result
As reported in the abstract
Twofold increase in 3/5 serotypes
Further findings
- Response to PPSV23, SLE vs healthy controls — Healthy controls
- 100%
Prednisolone use by response
- Non-responders on prednisolone
- 15
- Responders on prednisolone
- 41/54 (76%)
- No difference in other immunosuppressive drugs
- Increasing age predicted poor response on multivariable analysis in all serotypes
Safety
- Major adverse event: Miller Fisher variant of Guillain-Barré syndrome — Sequential
- 1 events
Minor adverse events
- Sequential, after conjugate vaccine: injection-site pain, migraine, fever, fatigue
- one each
- Sequential, after PPSV23: fever
- 1
- PPSV23: injection-site pain, herpes zoster, headache, fever
- one each
- Abstract states three minor AEs in the PPSV23 group
Disease flares
- PPSV23: minor flares
- 3
- Sequential: major flare
- 1
- Sequential: minor flare
- 1
Original publication
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus. Lupus Sci Med. Published 8 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →